AstraZeneca
-
Gefurulimab Obtains Implied License from CDE for gMG
Apr, 2023. AstraZeneca’s Gefurulimab injection(ALXN1720) obtains the Implied License from CDE for generalized myasthenia gravis clinical trial.
Apr, 2023. AstraZeneca’s Gefurulimab injection(ALXN1720) obtains the Implied License from CDE for generalized myasthenia gravis clinical trial.
